Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice.

Finally, the REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification) study, involving 30,449 patients with ASCVD randomized to receive anacetrapib 100 mg daily or placebo on top of statin therapy, demonstrated a highly significant reduction (rate ratio 0.91; p < 0.004) in the composite primary endpoint of coronary death, MI, or coronary revascularization [ 55 ].

also in 132,142 other papers